Omicron News and Research

RSS

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

Researchers surveyed a representative sample of the adult population of New York City, United States, to determine the prevalence of COVID-19.

30 May 2022

Researchers identify a human monoclonal antibody that could broadly neutralize several variants of SARS-CoV-2, SARS-CoV, and other coronaviruses

Researchers identified 10-40, a human monoclonal antibody with potent neutralizing activity against SARS-CoV, SARS-CoV-2, and related sarbecoviruses.

30 May 2022

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Researchers explored the virological profiles of novel SARS-CoV-2 Omicron variants.

30 May 2022

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Researchers reported findings of a systematic antigenic analysis of the circulating SARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4, and BA.5.

30 May 2022

Method for predicting neutralization and protection based on variant-specific antibody measurements to SARS-CoV-2 antigens

Researchers reported a method to predict neutralization and protection against SARS-CoV-2 antigens.

30 May 2022

Researchers report the case of a non-vaccinated patient coinfected with SARS-CoV-2 Omicron BA.1 and BA.2

A recent study published in The Lancet Microbe described the case of a non-vaccinated female coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 and BA.2 subvariants.

30 May 2022

Excess deaths in Canada during COVID-19 pandemic vary widely by province, analysis shows

An analysis of excess deaths in Canada during the COVID-19 pandemic shows wide variation by province and underscores the need for better and consistent data for current and future health crisis management.

30 May 2022

Investigating post-COVID complaints after Delta versus Omicron variant infections

A new study discusses whether infection with the SARS-CoV-2 Omicron variant increases the risk of post-COVID complaints Delta infection.

30 May 2022

Pediatric patients with prior COVID-19 or MIS-C are not protected against Omicron

Research drawing on the national Overcoming COVID-19 study, led by Boston Children's Hospital, and the hospital's own Taking On COVID-19 Together Group provides evidence that children who previously had COVID-19 (or the inflammatory condition MIS-C) are not protected against the newer Omicron variant.

27 May 2022

Exploring antigenic traits of SARS-CoV-2 Omicron BA.5 and BA.4 subvariants

Scientists analyzed the antigenic characteristics of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 and BA.4 sublineages.

27 May 2022

Short-term immunity imparted by COVID-19 BNT162b2 vaccination in adolescents and children

Researchers demonstrated the short-term protection conferred by the SARS-CoV-2 BNT162b2 vaccination in adolescents and children.

27 May 2022

Novavax missed its global moonshot but is angling to win over mRNA defectors

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its covid vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

26 May 2022

Study describes the symptom profiles of the main variants of SARS-CoV-2

Researchers assessed the severe SARS-CoV-2 variant-specific COVID-19 symptoms among residents of England.

26 May 2022

Nanotechnology enhanced DNA-chip for SARS-CoV-2 detection with variant differentiation

Researchers differentiated between SARS-CoV-2 variants using nanotechnology.

26 May 2022

Model predicts scenarios that reveal the benefit of updating COVID vaccines

In a recent study posted to the bioRxiv* preprint server, scientists analyzed the necessity of revamping the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines to tackle the current dominant circulating viral variants.

26 May 2022

Mucosal COVID vaccine candidate powerfully protective in macaques

A recent research paper posted to the bioRxiv* preprint server illustrated the protective efficacy of the intranasal pediatric parainfluenza virus-vectored coronavirus disease 2019 (COVID-19) vaccine prospect, B/HPIV3/S-6P, in macaques.

26 May 2022

SARS-CoV-2 variants BA.4 and BA.5 show substantial immune escape compared with BA.1 and BA.2

In a recent study posted to the bioRxiv* pre-print server, researchers characterized the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron’s new sub-lineages, BA.4, BA.5, and BA.3.

26 May 2022

A 6.4 million genome analysis predicts dominant SARS-CoV-2 variants

In this new study in the journal Science, researchers have developed a hierarchical Bayesian regression model, named, PyR0, which can analyze the complete set of publicly available SARS-CoV-2 genomes.

26 May 2022

Study illustrates risk of Omicron infection in fully vaccinated individuals

Scientists studied SARS-CoV-2 humoral responses in a healthy young person who was infected by the Omicron BA.1.15 after receiving booster vaccination.

25 May 2022

Vaccinated people with breakthrough SARS-CoV-2 infection can experience debilitating long COVID

Even vaccinated people with mild breakthrough COVID-19 infections can experience debilitating, lingering symptoms that affect the heart, brain, lungs and other parts of the body, according to new research from Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care System.

25 May 2022

Omicron News and Research

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

Researchers identify a human monoclonal antibody that could broadly neutralize several variants of SARS-CoV-2, SARS-CoV, and other coronaviruses

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Method for predicting neutralization and protection based on variant-specific antibody measurements to SARS-CoV-2 antigens

Researchers report the case of a non-vaccinated patient coinfected with SARS-CoV-2 Omicron BA.1 and BA.2

Excess deaths in Canada during COVID-19 pandemic vary widely by province, analysis shows

Investigating post-COVID complaints after Delta versus Omicron variant infections

Pediatric patients with prior COVID-19 or MIS-C are not protected against Omicron

Exploring antigenic traits of SARS-CoV-2 Omicron BA.5 and BA.4 subvariants

Short-term immunity imparted by COVID-19 BNT162b2 vaccination in adolescents and children

Novavax missed its global moonshot but is angling to win over mRNA defectors

Study describes the symptom profiles of the main variants of SARS-CoV-2

Nanotechnology enhanced DNA-chip for SARS-CoV-2 detection with variant differentiation

Model predicts scenarios that reveal the benefit of updating COVID vaccines

Mucosal COVID vaccine candidate powerfully protective in macaques

SARS-CoV-2 variants BA.4 and BA.5 show substantial immune escape compared with BA.1 and BA.2

A 6.4 million genome analysis predicts dominant SARS-CoV-2 variants

Study illustrates risk of Omicron infection in fully vaccinated individuals

Vaccinated people with breakthrough SARS-CoV-2 infection can experience debilitating long COVID

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News